Cancer staging is essential in determining the choice of therapy and in assessing prognosis.
The aim of the FORCE project is addressing exactly this crucial point.
We believe that MRF derived imaging biomarkers will allow for patient stratification prior to therapy and therapy efficacy control during therapy.

This has the potential to result in improved patient outcomes at reduced costs.

Impact for Breast Cancer
MRF imaging of the primary tumour could have a major impact in better delineation of the primary tumour in the breast to facilitate more accurate resection. Moreover MRF,  as imaging biomarker indicative of metastatic potential, could help guide treatment decisions with regard to neoadjuvant systemic therapy. 

 Impact for Liver Cancer (Hepatocellular Carcinoma)
The ability to predict ΜVI could allow candidates with good outcomes to be spared liver graft surgery. The ability to rule out ΜVI can allow patients to benefit from liver transplantation while they would have been excluded according to current, less accurate rules. It is expected that about 25% of current candidates for liver transplantation for HCC could be accurately re-allocated to an appropriate treatment strategy without waiting for obvious progression on the waiting list.

Impact for Intracranial Tumours
The assessment of the overall prognosis of the patient is one of the key elements in therapy planning.  MRF has the potential to provide valuable information on tumour margins and differentiation between cancer progression from pseudo-progression in differentiating the active tumour boundary from the surrounding viable tissue and quantifying effective therapy via a measured reduction in IFP.


The participation of major industrial and pharmaceutical partners in the project accelerates the time to market and encourages a prompt implementation.